Prot #CA224083: A Phase 1/2a Study to Evaluate the Safety, Tolerability, and Efficacy of Relatlimab Administered in Combination with Ipilimumab or Ipilimumab Alone in Participants with Unresectable or Metastatic Melanoma Who Have Progressed on Anti-PD-1 T

Project: Research project

StatusActive
Effective start/end date9/25/199/25/22

Funding

  • Bristol-Myers Squibb Company (Prot #CA224083)